BlackRock Discloses 5.0% Stake in Legend Biotech Corp.
Ticker: LEGN · Form: SC 13G · Filed: Jan 29, 2024 · CIK: 1801198
| Field | Detail |
|---|---|
| Company | Legend Biotech Corp (LEGN) |
| Form Type | SC 13G |
| Filed Date | Jan 29, 2024 |
| Risk Level | low |
| Sentiment | bullish |
Complexity: simple
Sentiment: bullish
Topics: institutional-ownership, passive-investment, pharmaceuticals
TL;DR
**BlackRock just revealed a 5.0% stake in Legend Biotech, a bullish signal from a big player.**
AI Summary
BlackRock Inc., a major investment firm, reported on January 29, 2024, that it holds a significant stake in Legend Biotech Corp. As of December 31, 2023, BlackRock beneficially owned 10,030,071 shares of Legend Biotech's Common Stock, representing 5.0% of the company. This filing indicates BlackRock's passive investment in the pharmaceutical company, signaling confidence from a large institutional investor, which could be a positive sign for current and prospective shareholders.
Why It Matters
This filing shows a major institutional investor, BlackRock, has a significant stake in Legend Biotech, which can be seen as a vote of confidence in the company's future prospects.
Risk Assessment
Risk Level: low — This filing indicates a passive, institutional investment, which generally reduces volatility and provides stability.
Analyst Insight
A smart investor would view BlackRock's 5.0% passive stake as a positive signal, suggesting institutional confidence in Legend Biotech, and might consider further research into the company's fundamentals.
Key Numbers
- 10,030,071 — Shares Owned (Total shares of Legend Biotech Common Stock beneficially owned by BlackRock Inc.)
- 5.0% — Ownership Percentage (Percentage of Legend Biotech's Common Stock owned by BlackRock Inc.)
- December 31, 2023 — Reporting Date (The date as of which BlackRock's ownership was calculated for this filing.)
Key Players & Entities
- BlackRock Inc. (company) — reporting person, institutional investor
- Legend Biotech Corp (company) — subject company, pharmaceutical preparations
- 10,030,071 (dollar_amount) — shares beneficially owned by BlackRock
- 5.0% (dollar_amount) — percentage of class owned by BlackRock
- December 31, 2023 (person) — date of event requiring filing
- January 29, 2024 (person) — filing date
Forward-Looking Statements
- Legend Biotech Corp's stock may experience increased investor confidence due to BlackRock's significant stake. (Legend Biotech Corp) — medium confidence, target: next 3-6 months
FAQ
What is the purpose of an SC 13G filing?
An SC 13G filing is used by institutional investors who acquire more than 5% of a company's stock but do not intend to influence or control the company. It's a 'passive' ownership disclosure, as indicated by the filing checking Rule 13d-1(b).
Which company is the subject of this SC 13G filing?
The subject company of this SC 13G filing is Legend Biotech Corp, a pharmaceutical preparations company with CIK 0001801198.
Who is the reporting person in this SC 13G filing?
The reporting person in this SC 13G filing is BlackRock Inc., a security brokers, dealers & flotation company with CIK 0001364742.
What percentage of Legend Biotech Corp's Common Stock does BlackRock Inc. beneficially own?
BlackRock Inc. beneficially owns 5.0% of Legend Biotech Corp's Common Stock, as stated in the filing.
As of what date was BlackRock Inc.'s ownership in Legend Biotech Corp reported?
BlackRock Inc.'s ownership in Legend Biotech Corp was reported as of December 31, 2023, which is the 'Date of Event Which Requires Filing of this Statement'.
Filing Details
This Form SC 13G (Form SC 13G) was filed with the SEC on January 29, 2024 by December 31, 2023 regarding Legend Biotech Corp (LEGN).